Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies

Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis

Ramalingam, Naveen PhD*; Jeffrey, Stefanie S. MD

doi: 10.1097/PPO.0000000000000308
Review Articles
Buy

Liquid biopsy provides minimally invasive and readily obtainable access to tumor-associated biological material in blood or other body fluids. These samples provide important insights into cancer biology, such as primary tumor heterogeneity; real-time tumor evolution; response to therapy, including immunotherapy; and mechanisms of cancer metastasis. Initial biological materials studied were circulating tumor cells and circulating nucleic acids, including circulating tumor DNA and microRNAs; more recently, studies have expanded to investigate extracellular vesicles, such as exosomes, microvesicles, and large oncosomes; tumor-derived circulating endothelial cells; and tumor-educated platelets. Even with an ongoing ambitious investment effort to develop liquid biopsy as an early cancer detection test in asymptomatic individuals, current challenges remain regarding how to access and analyze rare cells and tumor-derived nucleic acids in cancer patients. Technologies and associated bioinformatics tools are continuously evolving to capture these rare materials in an unbiased manner and to analyze them with high confidence. After first presenting recent applications of liquid biopsy, this review discusses aspects affecting the field, including tumor heterogeneity, single-cell analyses, and associated computational tools that will shape the future of liquid biopsy, with resultant opportunities and challenges.

From the *New Technologies Group, Fluidigm Corporation, South San Francisco; and †Division of Surgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA.

This review was supported in part by NCI IMAT grant R21CA177447 (to S.S.J.), Susan G. Komen Foundation SAB1500003 (to S.S.J.), and the John and Marva Warnock Research Fund (to S.S.J.).

Dr. Jeffrey has disclosed no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Dr. Ramalingam is an employee and stockholder of Fluidigm Corporation.

Reprints: Stefanie S. Jeffrey, MD, Medical School Lab Surge Bldg, P214, 1201 Welch Rd, Stanford, CA 94305. E-mail: ssj@stanford.edu.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.